Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine

• Published in: Drug resistance updates Vol. 60; p. 100806
• Main Authors: Van den bossche, Valentin, Zaryouh, Hannah, Vara-Messler, Marianela, Vignau, Julie, Machiels, Jean-Pascal, Wouters, An, Schmitz, Sandra, Corbet, Cyril
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.01.2022
• Subjects: Cancer-associated fibroblasts; Carcinoma, Squamous Cell - therapy; Head and neck cancer; Head and Neck Neoplasms - genetics; Head and Neck Neoplasms - therapy; Humans; Immunotherapy; Intratumoral heterogeneity; Metabolism; Precision Medicine; Squamous Cell Carcinoma of Head and Neck - genetics; Squamous Cell Carcinoma of Head and Neck - therapy; Therapy resistance; Tumor microenvironment; Tumor Microenvironment - genetics; DDR1; TAM; FAZA; CPS; SCCHN; OXPHOS; OPSCC; TAZ; IFN-γ; scRNA-seq; cfDNA; EMA; PFS; DAHANCA; IL; NSG; FGF; PUFA; EORTC; HGF; CAF; ARCON; MATH; Metabolism; EMT; PBMC; TCGA; NF; FA; NGS; NK; PD-1; FMISO; FDA; MRI; FDG; YAP; PDTO; TiME; ctDNA; EGFR; HPV; R/M; Cancer-associated fibroblasts; Therapy resistance; Precision medicine; TPS; PD-L1; miRNA; TGF-β; CTLA-4; TIGIT; PDTX; Intratumoral heterogeneity; CA; OSCC; HIF; OS; Tumor microenvironment; MCAM; Treg; TMB; FGFR; TME; ECM; CT; CTC; FAP; FAO; αSMA; FAS; Head and neck cancer; PET; 5-FU; MCT
• ISSN: 1368-7646; 1532-2084
• DOI: 10.1016/j.drup.2022.100806

Squamous cell carcinoma of the head and neck (SCCHN) is among the most prevalent cancer types worldwide. Despite multimodal therapeutic approaches that include surgical resection, radiation therapy or concurrent chemoradiation, targeted therapy and immunotherapy, SCCHN is still associated with a poor prognosis for patients with locally advanced or recurrent/metastatic (R/M) diseases. Although next-generation sequencing data from thousands of SCCHN patients have provided a comprehensive landscape of the somatic genomic alterations in this disease, genomic-based precision medicine is not implemented yet in routine clinical use since no satisfactory genetic biomarker has been identified for diagnosis, patient outcome prediction and selection of tailored therapeutic options. The lack of significant improvement in SCCHN patient survival over the last decades stresses the need for reliable predictive biomarkers and new therapeutic strategies for personalized clinical management of SCCHN patients. Targeting the SCCHN-associated microenvironment or the interaction of the latter with cancer cells may represent such paradigm shift in the development of new strategies to treat SCCHN patients, as exemplified by the recent implementation of immune checkpoint inhibitors to improve clinical outcomes by increasing anti-tumor immune responses in SCCHN patients. Several clinical trials are in progress in SCCHN patients to evaluate the activity of monoclonal antibodies and small-molecule inhibitors targeting the tumor microenvironment (TME) at different treatment settings, including combinations with adjuvant surgery, radiation therapy and chemotherapy. This review describes the current knowledge about the influence of the TME on intratumoral heterogeneity and clinical relapse in human SCCHN patients. More precisely, the role of hypoxia as well as the presence of non-cancer cells (e.g. cancer-associated fibroblasts and immune cells) on therapy response of SCCHN cells is highlighted. We also discuss relevant (pre)clinical models that may help integrate the microenvironment-tumor cell interplay in translational research studies for SCCHN. Finally, this review explores potential therapeutic strategies that may exploit the crosstalk between TME and SCCHN cells in order to implement fundamental changes in the tumor treatment paradigm of patients with locally advanced or R/M SCCHN.